| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |